Cure8 research brief
Bowel urgency is a common, distressing symptom in UC that harms quality of life. This phase 3b study reports that mirikizumab treatment was associated with notable reductions in urgency and improvements in multiple QoL measures over 28 weeks, which could be meaningful for people considering treatment options.
Adults with moderately-to-severely active ulcerative colitis; patients on or considering biologic therapy for UC; gastroenterologists and IBD researchers.
This report describes an open-label phase 3b trial in adults with moderately-to-severely active ulcerative colitis who had significant bowel urgency at baseline. Patients received IV mirikizumab induction doses followed by subcutaneous maintenance dosing through week 24, with outcomes assessed at weeks 12 and 28.
By week 28 a majority had a clinically meaningful reduction in urgency and many reached urgency remission; improvements were also seen in IBDQ scores, absorbent product use, sexual activity avoidance, incontinence scores, activity impairment, and anxiety symptoms.
The study uses novel patient-reported urgency measures (UNRS) and validated QoL instruments (IBDQ). Because the content supplied is an abstract-level report, the brief summarizes the study abstract rather than a full peer-reviewed paper.
Findings are drawn from the article abstract (open-label phase 3b LUCENT-URGE). Open-label design and abstract-level reporting mean results should be interpreted cautiously; review the full published paper and product information for complete safety and efficacy details.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
These results suggest mirikizumab can achieve multiple treatment goals at once — symptoms, objective inflammation measures, and steroid-free status — outcomes that matter to people with IBD because they reflect both...
A new FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderate-to-severe Crohn disease another treatment option with one-year trial data showing improved clinical remission and endoscopic healing versus...
The article reports regulatory approvals and clinical-trial results for Omvoh (mirikizumab), which could offer a new option for people with moderate–severe Crohn’s who still have disruptive symptoms like bowel urgency....
